Article ISI
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY  (2022)

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

Blauvelt, Andrew; Silverberg, Jonathan, I; Lynde, Charles W.; Bieber, Thomas; Eisman, Samantha; Zdybski, Jacek; Gubelin, Walter; Simpson, Eric L.; Valenzuela, Fernando; Criado, Paulo Ricardo; Lebwohl, Mark G.; Feeney, Claire; Khan, Tahira; Biswas, Pinaki; DiBonaventura, Marco; et. al.

Abstract

Background: The heterogeneous course of moderate-to-severe atopic dermatitis necessitates treatment flexibility.

Más información

Título según WOS: Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial
Título de la Revista: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volumen: 86
Número: 1
Editorial: MOSBY-ELSEVIER
Fecha de publicación: 2022
Página de inicio: 104
Página final: 112
DOI:

10.1016/J.JAAD.2021.05.075
Notas: ISI